A Retrospective Review of Patients With Proliferative Diabetic Retinopathy and Regression of PDR After Treatment With Ranibizumab
Latest Information Update: 02 Feb 2021
Price :
$35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 06 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 26 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.